Fresenius SE & Co KGaA
XETRA:FRE
Intrinsic Value
Fresenius SE & Co. KGaA is a healthcare group, which engages in the provision of products and services for dialysis, hospitals, and outpatient medical care. [ Read More ]
The intrinsic value of one FRE stock under the Base Case scenario is 67.05 EUR. Compared to the current market price of 27.28 EUR, Fresenius SE & Co KGaA is Undervalued by 59%.
Valuation Backtest
Fresenius SE & Co KGaA
Run backtest to discover the historical profit from buying and selling FRE stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Fresenius SE & Co KGaA
| Current Assets | 12.5B |
| Cash & Short-Term Investments | 2.6B |
| Receivables | 3.7B |
| Other Current Assets | 6.3B |
| Non-Current Assets | 32.8B |
| Long-Term Investments | 3.5B |
| PP&E | 10.8B |
| Intangibles | 17.6B |
| Other Non-Current Assets | 862m |
| Current Liabilities | 9.3B |
| Accounts Payable | 1.5B |
| Short-Term Debt | 569m |
| Other Current Liabilities | 7.3B |
| Non-Current Liabilities | 17B |
| Long-Term Debt | 13.2B |
| Other Non-Current Liabilities | 3.7B |
Earnings Waterfall
Fresenius SE & Co KGaA
|
Revenue
|
22.3B
EUR
|
|
Cost of Revenue
|
-17.2B
EUR
|
|
Gross Profit
|
5.1B
EUR
|
|
Operating Expenses
|
-3.9B
EUR
|
|
Operating Income
|
1.2B
EUR
|
|
Other Expenses
|
-1.8B
EUR
|
|
Net Income
|
-594m
EUR
|
Free Cash Flow Analysis
Fresenius SE & Co KGaA
FRE Profitability Score
Profitability Due Diligence
Fresenius SE & Co KGaA's profitability score is 44/100. The higher the profitability score, the more profitable the company is.
Score
Fresenius SE & Co KGaA's profitability score is 44/100. The higher the profitability score, the more profitable the company is.
FRE Solvency Score
Solvency Due Diligence
Fresenius SE & Co KGaA's solvency score is 37/100. The higher the solvency score, the more solvent the company is.
Score
Fresenius SE & Co KGaA's solvency score is 37/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
FRE Price Targets Summary
Fresenius SE & Co KGaA
According to Wall Street analysts, the average 1-year price target for FRE is 35.98 EUR with a low forecast of 28.28 EUR and a high forecast of 45.15 EUR.
Shareholder Return
FRE Price
Fresenius SE & Co KGaA
| Average Annual Return | -12.31% |
| Standard Deviation of Annual Returns | 11.17% |
| Max Drawdown | -57% |
| Market Capitalization | 15.4B EUR |
| Shares Outstanding | 563 236 992 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Fresenius SE & Co. KGaA is a healthcare group, which engages in the provision of products and services for dialysis, hospitals, and outpatient medical care. The company is headquartered in Bad Homburg Vor Der Hohe, Hessen and currently employs 316,078 full-time employees. The company operates through four business segments. Fresenius Medical Care runs a global network of dialysis clinics, providing treatment for patients with chronic kidney failure. The company also offers dialyzers, dialysis machines and renal pharmaceuticals. Fresenius Kabi specializes in intravenously administered generic drugs (IV drugs), clinical nutrition and infusion therapies. The company also supplies hospitals with medical devices and products of transfusion technology. Fresenius Helios is a private hospital operator, with over 130 facilities in Germany, including maximum care hospitals and rehabilitation centers and, through Quironsalud, over 80 hospitals and outpatient centers, as well as approximately 300 Occupational Risk Prevention Centers in Spain. Fresenius Vamed manages projects and provides services for health care facilities worldwide, from development and turnkey construction to maintenance and total operational management.
Contact
IPO
Employees
Officers
The intrinsic value of one FRE stock under the Base Case scenario is 67.05 EUR.
Compared to the current market price of 27.28 EUR, Fresenius SE & Co KGaA is Undervalued by 59%.
You don't have any saved screeners yet
